Ocular Adnexal Lymphoma: Epidemiology and Clinical Characteristics


Creative Commons License

BATU OTO B., Kilicarslan O., SARICI A. M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.2, ss.119-125, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4999/uhod.225970
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.119-125
  • Anahtar Kelimeler: Ocular adnexal lymphoma, Orbital lymphoma, Conjunctival lymphoma, Extranodal marginal zone lymphoma, TNM staging, NON-HODGKINS-LYMPHOMA, CLASSIFICATION, OUTCOMES
  • İstanbul Üniversitesi Adresli: Hayır

Özet

The aim of the study is to emphasize the frequency, clinical presentation, histopathologic features and TNM staging for each type of ocular adnexal lymphoma (OAL), and investigating treatment results and prognosis in our region. A retrospective review of 54 patients treated for primary and secondary OAL between Jan 2012 and Jan 2019 was made. Epidemiologic data, clinical characteristics of the tumor and recurrence free survival rates were evaluated. Patients with ocular adnexal lymphoma included 27 (50%) women and 27 (50%) men, with a mean age of 60.38 +/- 15.36 (range: 18-93) years at the time of presentation. Mean follow-up time was 40.88 +/- 20.75 (range 1-84) months. Histopathological diagnosis was extranodal marginal zone lymphoma in 75.9%, diffuse large B-cell lymphoma in 14.8%, chronic lymphocytic leukemia/small lymphocytic lymphoma in 5.6%, mantle cell lymphoma in 1.9% and follicular cell lymphoma in 1.9% of patients. Among 54 patients with OAL 66.7% had orbital, 22.2% had conjunctival, 5.6% had orbital plus conjunctival, 3.7% had orbital plus conjunctival and choroidal, 1.9% had conjunctival plus choroidal involvement. No recurrences were observed in 87.1% of patients during their follow-up. Our data indicates patient epidemiologic data, TNM staging, most common clinical presentation and location of primary and secondary OALs from a single center.